Cyclo Therapeutics Signs Agreement with Worldwide Clinical Trials

- October 30th, 2019

The trial for Alzheimer’s disease will evaluate the company’s Trappsol Cyclo, which will be given by intravenous infusion.

Cyclo Therapeutics (OTCQB:CTDH) has announced it has signed an agreement with Worldwide Clinical Trials to start a clinical trial to evaluate safety and efficacy in Alzheimer’s Disease.

As quoted in the press release:

The trial will evaluate Trappsol® Cyclo™ given by intravenous infusion. The Company has previously reported encouraging data on safety and efficacy of the product based on an FDA-approved expanded access program in a single patient with late-onset Alzheimer’s Disease.

Alzheimer’s Disease affects 5.7 million Americans. While a few symptomatic treatments are available, there are no approved disease modifying treatments.

“We are very excited to work with Worldwide, an industry leader, on this critical clinical program,” said N. Scott Fine, Company Chairman and CEO. “Our work to advance an innovative approach to treat this devastating disease may lead to improvements in the lives of Alzheimer’s patients and their families. We are pleased to have Worldwide’s team of experts working closely with us as we begin our development pathway.”

“The scientific, medical and operational experts at Worldwide offer nearly 40 years of hard-won insight gleaned from our experience on the front lines of Alzheimer’s Disease research. The journey toward halting progression of this devastating neurodegenerative disorder takes tenacity, and we’re not about to give up now,” said Henry Riordan, executive vice president, Scientific Solutions, for Worldwide. “We are thrilled to be selected by the innovators at Cyclo Therapeutics as their partner in the development of this exciting new treatment approach.”

Click here to read the full press release.

Biotech Investing: Top Stocks and Future Prospects

 
Read out 2020 biotech marketing outlook report!

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply